ClinConnect ClinConnect Logo
Search / Trial NCT00235989

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Launched by BAYER · Oct 10, 2005

Trial Information

Current as of July 23, 2025

Completed

Keywords

Relapsing Multiple Sclerosis Interferon Beta 1b Betaferon Betaseron

ClinConnect Summary

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Signed and dated statement of informed consent
  • Completion of Protocol 307000A
  • Negative serum pregnancy test results
  • Agreement to adequate contraception, for female patients
  • Exclusion Criteria:
  • Pregnancy or lactation
  • History of alcohol or drug abuse
  • Inability to administer subcutaneous injections either by self or by caregiver
  • Medical, psychiatric or other conditions that compromise the patient's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study
  • Any significant change in the patient's medical condition after enrollment in Study 307000A which would have lead to his/her exclusion from participation that study

About Bayer

Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.

Locations

Los Angeles, California, United States

Kansas City, Missouri, United States

Chicago, Illinois, United States

Winston Salem, North Carolina, United States

San Francisco, California, United States

Chicago, Illinois, United States

Winston Salem, North Carolina, United States

Nashville, Tennessee, United States

Ann Arbor, Michigan, United States

Louisville, Kentucky, United States

Atlanta, Georgia, United States

Los Angeles, California, United States

Durham, North Carolina, United States

Stony Brook, New York, United States

Atlanta, Georgia, United States

Nashville, Tennessee, United States

Kansas City, Missouri, United States

San Francisco, California, United States

Columbus, Mississippi, United States

High Point, North Carolina, United States

Washington, District Of Columbia, United States

Reno, Nevada, United States

Washington, District Of Columbia, United States

Stony Brook, New York, United States

Patients applied

0 patients applied

Trial Officials

Bayer Study Director

Study Director

Bayer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials